Isabel Kalofonos - 05 Jan 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Commercial Officer
Signature
/s/ Tobin Schilke, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
05 Jan 2026
Net transactions value
-$36,025
Form type
4
Filing time
07 Jan 2026, 17:11:26 UTC
Previous filing
13 Jan 2025
Next filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kalofonos Isabel Chief Commercial Officer C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO /s/ Tobin Schilke, as attorney-in-fact 07 Jan 2026 0001975163

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $101,475 +2,500 +300% $40.59 3,334 05 Jan 2026 Direct F1
transaction CRNX Common Stock Sale $137,500 -2,500 -75% $55.00 834 05 Jan 2026 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Options Exercise $0 -2,500 -2.5% $0.000000 97,500 05 Jan 2026 Common Stock 2,500 $40.59 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan.
F2 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2025.
F3 The common stock was sold by the Reporting Person in an open market transaction on the transaction date, at a sale price of $55.00 per share.
F4 The option is exercisable as follows: 25% of the shares subject to the option vested on December 16, 2025, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.